Flag of the European Union EU Clinical Trials Register Help

Clinical trials for abbvie

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37587   clinical trials with a EudraCT protocol, of which   6160   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: abbvie. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-001227-12 Sponsor Protocol Number: M19-850 Start Date*: 2020-03-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study
    Medical condition: Moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing) FI (Ongoing) HU (Ongoing) ES (Ongoing) NL (Ongoing) FR (Ongoing) GB (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002491-26 Sponsor Protocol Number: M15-942 Start Date*: 2017-03-17
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination with Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experien...
    Medical condition: Chronic Hepatitis C Infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) SE (Ongoing) ES (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000221-39 Sponsor Protocol Number: M15-539 Start Date*: 2017-12-14
    Sponsor Name:AbbVie Inc
    Full Title: A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infectio...
    Medical condition: Severe Respiratory Syncytial Virus (RSV) Infection
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002264-57 Sponsor Protocol Number: M16-046 Start Date*: 2019-07-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermat...
    Medical condition: moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) FI (Ongoing) GB (Ongoing) NL (Ongoing) SE (Completed) FR (Ongoing) HU (Ongoing) ES (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000452-24 Sponsor Protocol Number: M13-576 Start Date*: 2017-03-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinic...
    Medical condition: Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002350-13 Sponsor Protocol Number: M15-410 Start Date*: 2016-01-18
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adu...
    Medical condition: Hepatitis C Virus (HCV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001398-17 Sponsor Protocol Number: M16-109 Start Date*: 2017-10-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination with Ruxolitinib in Subjects with Myelofibrosis
    Medical condition: Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001772-38 Sponsor Protocol Number: M14-239 Start Date*: 2019-01-29
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) IE (Ongoing) FR (Ongoing) GB (Ongoing) GR (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003073-26 Sponsor Protocol Number: M13-102 Start Date*: 2013-10-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) ES (Completed) HU (Prematurely Ended) AT (Completed) BE (Completed) DK (Completed) PT (Completed) PL (Completed) CZ (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000268-26 Sponsor Protocol Number: M15-570 Start Date*: 2019-06-25
    Sponsor Name:AbbVie Deutschland
    Full Title: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Ongoing) BE (Ongoing) DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001590-16 Sponsor Protocol Number: M15-563 Start Date*: 2019-07-02
    Sponsor Name:AbbVie Deutschland
    Full Title: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
    Medical condition: Progressive Supranuclear Palsy (PSP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-003046-87 Sponsor Protocol Number: M15-997 Start Date*: 2017-03-01
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A multicenter, open Label study to assess the safety and efficacy of rIsankizuMab for MaInTenance in moderate to severe pLaquE type pSoriaSis (LIMMITLESS)
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) SE (Ongoing) BE (Ongoing) DE (Ongoing) FI (Ongoing) CZ (Ongoing) PL (Ongoing) PT (Ongoing) ES (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000715-25 Sponsor Protocol Number: M15-340 Start Date*: 2019-04-16
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Open-Label Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects with Polyarticular Course Juvenile Idiopathic Arthritis
    Medical condition: Polyarticular Course Juvenile Idiopathic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) HU (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003669-87 Sponsor Protocol Number: M14-064 Start Date*: 2018-03-19
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
    Medical condition: metastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplatin and bevacizumab
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005398-18 Sponsor Protocol Number: W15-679 Start Date*: 2016-07-12
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Treating patients with early axial spondyloarthritis to target – a 1 year randomized controlled study taking an intense treatment approach versus routine treatment (STRIKE)
    Medical condition: Axial spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10071400 Axial spondyloarthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000439-14 Sponsor Protocol Number: M13-833 Start Date*: 2018-03-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients with Relapsed or Refractory Malignancies
    Medical condition: In Part 1 patients with any relapsed or refractory tumor will be eligible to enroll. During Part 2 patients with the following malignancies: acute lymphoblastic leukemia (ALL), acute myeloid leu...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing) GB (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000750-63 Sponsor Protocol Number: M19-530 Start Date*: 2019-10-31
    Sponsor Name:AbbVie Deutschland
    Full Title: A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Ongoing) HU (Ongoing) NL (Ongoing) BE (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003053-21 Sponsor Protocol Number: M16-560 Start Date*: 2019-06-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Randomized, Double-Blind, Double-Dummy, Active Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Subjects with Moderate to Severe Rheumatoid Arth...
    Medical condition: Moderate to Severe Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003753-29 Sponsor Protocol Number: M19-148 Start Date*: 2020-05-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke
    Medical condition: Acute Ischemic Stroke
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003752-36 Sponsor Protocol Number: M16-077 Start Date*: 2020-05-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
    Medical condition: Spinal cord injury (SCI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA